Patents Assigned to Minerva Biotechnologies Corporation
  • Publication number: 20130190495
    Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.
    Type: Application
    Filed: December 7, 2012
    Publication date: July 25, 2013
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: MINERVA BIOTECHNOLOGIES CORPORATION
  • Patent number: 8349853
    Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: January 8, 2013
    Assignee: Minerva Biotechnologies Corporation
    Inventor: Cynthia C. Bamdad
  • Patent number: 8344113
    Abstract: The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: January 1, 2013
    Assignee: Minerva Biotechnologies Corporation
    Inventor: Cynthia C. Bamdad
  • Publication number: 20100124789
    Abstract: Porous members can be positioned so as to partially or fully span channels in microfluidic systems. The porous members can be assembled and/or disassembled in situ. The porous members can be made such that pores are separated by connections including but a single molecule at one location, allowing for a high level of open area in a very small pore size member. The porous member can be made up of colloid particles interconnected with molecular species. These can be used to detect analytes qualitatively and/or quantitatively, or to selectively bind and/or release agents on command for a variety of purposes including first blocking, then opening a channel, concentrating analyte over time followed by release of analyte and detection downstream, etc. Porous members can define valves in multiple-channel systems and, with controlled binding and release of agents at the porous members, these valves can be opened and closed and fluid flow controlled in a multi-channel system.
    Type: Application
    Filed: November 5, 2009
    Publication date: May 20, 2010
    Applicant: Minerva Biotechnologies Corporation
    Inventor: Cynthia C. BAMDAD
  • Patent number: 7700715
    Abstract: The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: April 20, 2010
    Assignee: Minerva Biotechnologies Corporation
    Inventors: Cynthia C. Bamdad, R. Shoshana Bamdad
  • Patent number: 7615340
    Abstract: Porous members can be positioned so as to partially or fully span channels in microfluidic systems. The porous members can be assembled and/or disassembled in situ. The porous members can be made such that pores are separated by connections including but a single molecule at one location, allowing for a high level of open area in a very small pore size member. The porous member can be made up of colloid particles interconnected with molecular species. These can be used to detect analytes qualitatively and/or quantitatively, or to selectively bind and/or release agents on command for a variety of purposes including first blocking, then opening a channel, concentrating analyte over time followed by release of analyte and detection downstream, etc. Porous members can define valves in multiple-channel systems and, with controlled binding and release of agents at the porous members, these valves can be opened and closed and fluid flow controlled in a multi-channel system.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: November 10, 2009
    Assignee: Minerva Biotechnologies Corporation
    Inventor: Cynthia C. Bamdad
  • Publication number: 20060024230
    Abstract: Customized therapeutics and in situ diagnostics for patient therapy and diagnosis takes advantage of tools including techniques for derivatizing colloids with self-assembled monolayers. This provides the capability of a wide variety of assays including chemical or biochemical agent/agent interaction studies. Bio-derivatized colloids, with or without signaling entities, are used to probe interactions with species on non-colloidal structures. The invention provides techniques for immobilizing colloidal particles on a wide variety of non-colloidal structures. Included is the ability to decorate a variety of non-colloidal structures including beads, with colloids as a detectable assay. This allows, in many cases, assays detectable via the unaided human eye, as well as assays detectable via automated determination of a change of interaction of electromagnetic radiation with the colloids, e.g., absorption, light-scattering, and the like.
    Type: Application
    Filed: September 22, 2003
    Publication date: February 2, 2006
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
  • Publication number: 20050202402
    Abstract: Chemical, biological, and/or biochemical assays of the invention utilize intermediate binding entities for binding interactions. For example, a colloid particle carrying a species that could harm a component in the assay is allowed to binding interact in the assay only after other, more sensitive components have finished their binding interactions. In another example, multi-step binding interactions are used where single-step interactions could be used, so as to reduce false positives.
    Type: Application
    Filed: August 27, 2004
    Publication date: September 15, 2005
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
  • Publication number: 20050186635
    Abstract: The invention provides compositions, kits, methods, and species that include electroactive entities which can serve as signaling entities in chemical and/or biochemical assays. The electroactive species can be metallocenes, such as ferrocenes, including substituents that affect the oxidation/reduction potential (redox potential) of the species. By controlling the redox potential of the species, multiple species can be used in a single assay, each species having a different redox potential, for simultaneous signaling of different binding events. Additionally, species having redox potentials lower than 490 mV can be provided, allowing signaling within a potential range easily detectable in the presence of biological fluids.
    Type: Application
    Filed: August 6, 2004
    Publication date: August 25, 2005
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Shoshana Shendelman, Michael Frid
  • Publication number: 20050064446
    Abstract: The invention provides novel techniques for determining the interaction between binding partners. The first binding partner is immobilized to a surface or a colloid and a second binding partner immobilized to a surface or a colloid. Non-specific binding techniques, including a SAM, provide for the immobilization of a wide variety of species. A mixture may be separated into various components and these components may then be fastened to either the colloids or the surfaces. Binding interaction between the binding partners may be determined through a variety of assays.
    Type: Application
    Filed: January 23, 2004
    Publication date: March 24, 2005
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
  • Publication number: 20050053964
    Abstract: Methods, assays, and components are described in which biological samples can be rapidly and sensitively analyzed for the presence of species associated with neurodegenerative disease. Techniques and components are provided for diagnosis of disease, as well as for screening of candidate drugs for treatment of neurodegenerative disease. The techniques are simple, extremely sensitive, and utilize readily-available components. Binding species, capable of binding a neurodegenerative disease aggregate-forming or aggregate-forming species, are fastened to surfaces of electrodes and surfaces of particles, or provided free in solution, to bind aggregate-forming species and/or be involved in aggregation.
    Type: Application
    Filed: January 13, 2004
    Publication date: March 10, 2005
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Shoshana Shendelman
  • Publication number: 20050014784
    Abstract: A treatment for cancer is provided. The treatment may include administering a therapeutic amount of L-histidine, D-cycloserine, quisqualic acid or suramin or analogs thereof.
    Type: Application
    Filed: November 14, 2003
    Publication date: January 20, 2005
    Applicant: Minerva Biotechnologies Corporation
    Inventors: R. Shendelman, Cynthia Bamdad
  • Patent number: 6723517
    Abstract: Weak binding motifs were transformed into a high affinity ligand surface by using a heterologous self-assembled monolayer (SAM) as a rigid scaffold to present discrete binding moieties, in a controlled geometry, to a target molecule. At a critical ligand density, the discrete binding moieties simulated a multivalent ligand and promoted high-affinity, cooperative binding of the target molecule. Statistical calculations were applied to SAM components in solution and gold-sulfur packing dimensions to extract the inter-ligand-distance within the SAM. This distance information is valuable to the rational design of multivalent drugs.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: April 20, 2004
    Assignee: Minerva Biotechnologies Corporation
    Inventor: Cynthia Carol Bamdad